Satellos to Host KOL Event on SAT-3247 for Duchenne Muscular Dystrophy

summarizeSummary

Satellos Bioscience announced it will host a virtual Key Opinion Leader (KOL) event featuring Dr. Kevin M. Flanigan to discuss SAT-3247 for Duchenne Muscular Dystrophy, providing updates on its clinical development.

check_boxKey Events

• Virtual KOL Event Announced

  Satellos Bioscience will host a virtual Key Opinion Leader (KOL) event on February 24, 2026, at 3:30 p.m. ET.

• Featured Expert

  The event will feature Dr. Kevin M. Flanigan, a prominent expert in neuromuscular research and Director of the Center for Gene Therapy at Nationwide Children's Hospital.

• Focus on SAT-3247 for DMD

  Discussions will cover the unmet need and current treatment landscape for Duchenne Muscular Dystrophy (DMD), along with an overview of Satellos' SAT-3247, including Phase 1a/b results and updates on ongoing Phase 2 studies (TRAILHEAD and BASECAMP).

auto_awesomeAnalysis

Satellos Bioscience is hosting a virtual Key Opinion Leader (KOL) event to provide a deeper dive into its lead drug candidate, SAT-3247, for Duchenne Muscular Dystrophy (DMD). The involvement of Dr. Kevin M. Flanigan, a highly respected expert in neuromuscular research, lends significant credibility to the discussion. This event serves to educate investors and the scientific community on the unmet need in DMD, the current treatment landscape, and the progress of SAT-3247, including results from completed Phase 1a/b trials and updates on ongoing Phase 2 studies. Coming shortly after the company finalized a public offering and announced the dosing of its Phase 2 pediatric study, this KOL event strategically reinforces the scientific foundation and clinical potential of their core asset, potentially boosting investor confidence, especially with the stock trading near its 52-week low.